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**What was known?**

It has already been established that psoriatic patients have fewer nevi than normal population.

Psoriasis is a persistent, chronic inflammatory disease that affects up to 2% of the population.\[[@ref1]\] Several researches demonstrated a relation between psoriasis and comorbidities, such as metabolic syndrome, cardiovascular diseases, inflammatory bowel diseases, depression/suicide, and risk of cancers.\[[@ref2][@ref3][@ref4][@ref5][@ref6]\]

Although many studies show that the risk of melanoma and nonmelanoma skin cancer in patients with psoriasis is comparable with the general population, patients with psoriasis who have received more than 250 psoralen plus ultraviolet A (PUVA) treatments have a 14-fold higher risk of cutaneous squamous cell carcinoma than patients who have received fewer treatments.\[[@ref7][@ref8][@ref9]\]

There are contradictory results about the relationship between melanoma and psoriasis in literature. Although there is evidence that Caucasians with extensive PUVA exposure have an increased risk of melanoma, other studies have found no significant association between psoriasis and melanoma.\[[@ref10][@ref11]\] However, little is known about the association of melanocytic nevi with psoriasis. Previous studies on the influence of psoriasis vulgaris on the number of melanocytic nevi showed that patients affected with psoriasis vulgaris have fewer nevi compared with controls, and that the immunologic environment with regard to interleukin (IL-1α), IL-6, and tumor necrosis factor alpha (TNF-α) serum levels influences the number of nevi with an inverse correlation.\[[@ref12][@ref13]\] The aims of this study were to investigate the number of melanocytic lesions in psoriatic patients and to assess whether there is an association between the severity of psoriasis, psoriasis therapies, and nevus count.

Methods {#sec1-2}
=======

We performed a prospective study on patients with psoriasis vulgaris, who were recruited from those consecutively attending the outpatient clinics of department of Dermatology at Bezmialem Vakif University, Istanbul, Turkey, from July through December 2015. One hundred psoriatic patients and 100 controls, with no family history of psoriasis, were enrolled in the study.

The study was approved by the local Ethics Committee. Informed consent was obtained from all participants, and the study was conducted according to the Declaration of Helsinki Principles.

Age at diagnosis of psoriasis, clinical characteristics; family history of psoriasis, Psoriasis Area and Severity Index score at enrollment, and previous and current therapies were registered. Treatments were classified as topical agents, phototherapy, cyclosporine, methotrexate, retinoids, and biologics.

For all the participants, melanocytic nevi ≥2 mm were counted on all body sites.
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### Statistical analysis {#sec3-1}

Continuous variables were compared using Student\'s *t*-test and Mann--Whitney U-test. Comparisons between categorical variables were performed with Chi-square test and Fisher corrections, when required. *P* \< 0.05 was considered statistically significant.

Results {#sec1-3}
=======

A total of 200 participants, 100 psoriatic patients and 100 controls, were included in the study \[[Table 1](#T1){ref-type="table"}\]. In the psoriasis group, a family history of psoriasis was reported by 27 of the 100 (27%) patients, and none of the patients had a personal history of melanoma; the mean age of disease onset was 26.07 ± 17.39 (range: 0--71 years), and a diagnosis of psoriatic arthritis was made in 21 of the 100 (21%) patients.

###### 

Demographic features of patients
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Mild psoriasis was diagnosed in 82 of the 100 (82%) patients, and moderate-to-severe psoriasis was diagnosed in 18 of the 100 (18%) patients. There are no statistically significant differences related to nevi count between mild psoriasis group and moderate-to-severe psoriasis group (*P*: 0.803). At enrollment, 38 of the 100 (38%) patients were treated with topical agents alone, 21 of the 100 (21%) with narrowband ultraviolet B, and 15 of the 100 (15%) with biologic agents. Overall, 75 of the 100 (75%) patients were treated at least once in their life with a conventional systemic treatment.

We found a wide variation in the total number of nevi both in psoriasis and control groups (from 0 to 100). Psoriatic patients had fewer nevi than controls, both in the overall nevus count (*P*: 0.002) \[[Table 2](#T2){ref-type="table"}\].

###### 

Nevus count of patients
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Psoriatic patients were less likely to have congenital nevi (7 of 100; 7%) than controls (20 of 100; 20%) (*P*: 0.036). We did not find any association between therapies and nevi count (*P*: 0.213). Disease duration, presence of psoriatic arthritis, and previous exposure to phototherapy were not significantly associated with nevus count (*P*: 0.073) (*P*: 0.707) (*P*: 0.815).

Discussion {#sec1-4}
==========

Psoriasis is usually presented as erythematous, raised, scaly skin lesions. Histology of psoriasis is characterized by parakeratosis and psoriasiform hyperplasia. Abnormal expression of T-helper 1 (Th1), Th17 cells, and overproduction of pro-inflammatory cytokines, particularly TNF-α, interferon gamma (IFN-g), IL-2, and IL-12 has a major role on the pathogenesis of psoriasis. Therefore, the pathogenesis of psoriasis is considered to be an immunologically mediated process.

Secreted cytokines from activated cells induce epidermal acanthosis, hyperkeratosis, and parakeratosis, which characterize psoriasis plaques. Psoriasis is considered a Th1 condition, characterized by the production of IFN-g and TNF-α with the effect of IL-12. In the recent years, the importance of Th17 cells has been estimated in psoriasis. Th17 cells are stimulated by IL-23 (which shares the p40 subunit with IL-12) to produce IL-17 and also IL-22, which has recently been shown to be a major driver of acanthosis in psoriasis. The IL-23/Th17 axis may explain the hyperplasia of psoriatic keratinocytes by IL-22.\[[@ref14]\]

One of the most common histopathological findings in psoriasis lesions is an increase in epidermal proliferation and parakeratosis. The scaling is caused by thickened stratum corneum with parakeratosis and epidermal thickening with acanthosis, papillomatosis, and absence of granular layer.

We found that psoriatic patients had significantly fewer nevi than controls. Twenty-three of the 100 patients versus 2 of the 100 healthy controls had no nevi and 65% of the (65 of 100) patients versus 20% (20 of 100) of the controls had 1--10 nevi. Two patients versus 28 of the healthy controls had more than 50 nevi.

Balato *et al*. showed that 22% of the patients had 0 nevi versus 1.1% of the controls, and that the global number of nevi ranged from 0 to 30 in psoriatic patients and from 0 to over 50 in controls.\[[@ref12]\] Di Cesare *et al*. reported that controls had more congenital nevi compared with patients (44 of 189 \[23.2%\] and 20 of 189 \[10.6%\], respectively). In addition, they detected a very low percentage of clinical atypical nevi and no melanoma in both patients and controls.\[[@ref13]\] Our results are consistent with Balato *et al*. and Di Cesare *et al*.

In line with Di Cesare *et al*., no relationship between the number of nevi and severity of disease, age at diagnosis, duration of psoriasis, metabolic comorbidities, obesity, phototherapy, and presence of psoriatic arthritis was found in our study.

Major cytokines in the pathogenesis of psoriasis are TNF-α, IL-1, IL-6, and transforming growth factor-β, which inhibit tyrosinase activity.\[[@ref15]\] Immunosuppressive and immunomodulating agents which were used in the treatment of psoriasis vulgaris may lead to change in the cytokine profile. Patients with Crohn\'s disease had eruptive nevi during immunosuppressive therapies, including anti-TNF-α treatment.\[[@ref16]\] Rapid development of melanoma has been recently reported in two patients treated with an anti-IL-6 agent, tocilizumab.\[[@ref17][@ref18]\] In our study, patients treated with biologic agents did not have more nevi than patients treated otherwise. It may be the result of low sample size of biologic agents in our study. No cases of melanoma were detected in patients with psoriasis and their family.

Wang *et al*. reported the presence of Th17 cells in the skin lesions of vitiligo.\[[@ref19]\] They showed that IL-17 by itself does not inhibit pigmentation signaling; however, IL-17 can increase the inhibitory effect of TNF on melanogenesis significantly. In addition, Kotobuki *et al*. reported that a combination of TNF, IL-1β, IL-6, and IL-17 could inhibit melanin production.\[[@ref20]\] They showed that IL-17A dramatically induced IL-1β, IL-6, and TNF-α production in skin-resident cells such as keratinocytes and fibroblasts. This local environment results in local depigmentation in autoimmune vitiligo lesions.

It was also shown that TNF, IL-6, IL-1α, and TGF-β1 could independently modulate the expression of tyrosinase and related enzymes.\[[@ref21]\] In addition, Yang *et al*. showed that IFN-g inhibits melanogenesis in primary cultured human melanocytes by altering melanogenic enzyme messenger RNA expression in addition to increased melanocyte apoptosis via direct affect of IFN-g.\[[@ref22]\]

Conclusions {#sec1-5}
===========

Psoriatic patients have fewer melanocytic nevi than controls, suggesting a protective role of the cytokine profile of psoriasis and increased secretion of IL-17, TNF, IL-6, and IL-1β against the development of melanocytic lesions. The protective role of genetic background against melanoma and nonmelanoma skin cancers should be investigated in the relatives of psoriasis patients.
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**What is new?**

It was shown that treatment modality for psoriasis does not affect the number of nevi and patients who undergone biologic agents do not have more nevi than other psoriatic patients.
